Literature DB >> 18650448

Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface.

Hironao Wakabayashi1, Fatbardha Varfaj, Jennifer Deangelis, Philip J Fay.   

Abstract

Factor VIII consists of a heavy chain (A1A2B domains) and light chain (A3C1C2 domains), whereas the contiguous A1A2 domains are separate subunits in the cofactor, factor VIIIa. The intrinsic instability of the cofactor results from weak affinity interactions of the A2 subunit within factor VIIIa. The charged residues Glu272, Asp519, Glu665, and Glu1984 appear buried at the interface of the A2 domain with either the A1 or A3 domain, and thus may impact protein stability. To determine the effects of these residues on procofactor/cofactor stability, these residues were individually replaced with either Ala or Val, and stable BHK cell lines expressing the B-domainless proteins were prepared. Specific activity and thrombin generation parameters for 7 of the 8 variants were more than 80% the wild-type value. Factor VIII activity at 52 degrees C to 60 degrees C and the decay of factor VIIIa activity after thrombin activation were monitored. Six of the 7 variants showing wild-type-like activity demonstrated enhanced stability, with the Glu1984Val variant showing a 2-fold increase in thermostability and an approximately 4- to 8-fold increase in stability of factor VIIIa. These results indicate that replacement of buried charged residues is an effective alternative to covalent modification in increasing factor VIII (VIIIa) stability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650448      PMCID: PMC2556611          DOI: 10.1182/blood-2008-02-142158

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

Review 1.  Regulation of factor VIII expression and activity by von Willebrand factor.

Authors:  R J Kaufman; S W Pipe
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Ca(2+) binding to both the heavy and light chains of factor VIII is required for cofactor activity.

Authors:  Hironao Wakabayashi; Kyla M Schmidt; Philip J Fay
Journal:  Biochemistry       Date:  2002-07-02       Impact factor: 3.162

Review 3.  Activation of factor VIII and mechanisms of cofactor action.

Authors:  Philip J Fay
Journal:  Blood Rev       Date:  2004-03       Impact factor: 8.250

4.  Residues 110-126 in the A1 domain of factor VIII contain a Ca2+ binding site required for cofactor activity.

Authors:  Hironao Wakabayashi; Jan Freas; Qian Zhou; Philip J Fay
Journal:  J Biol Chem       Date:  2004-01-13       Impact factor: 5.157

5.  Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.

Authors:  S W Pipe; R J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Hemophilia A mutations within the factor VIII A2-A3 subunit interface destabilize factor VIIIa and cause one-stage/two-stage activity discrepancy.

Authors:  William H Hakeos; Hongzhi Miao; Nongnuch Sirachainan; Geoffrey Kemball-Cook; Evgueni L Saenko; Randal J Kaufman; Steven W Pipe
Journal:  Thromb Haemost       Date:  2002-11       Impact factor: 5.249

7.  Metal ion-independent association of factor VIII subunits and the roles of calcium and copper ions for cofactor activity and inter-subunit affinity.

Authors:  H Wakabayashi; M E Koszelak; M Mastri; P J Fay
Journal:  Biochemistry       Date:  2001-08-28       Impact factor: 3.162

8.  Calibrated automated thrombin generation measurement in clotting plasma.

Authors:  H Coenraad Hemker; Peter Giesen; Raed Al Dieri; Véronique Regnault; Eric de Smedt; Rob Wagenvoord; Thomas Lecompte; Suzette Béguin
Journal:  Pathophysiol Haemost Thromb       Date:  2003

9.  An engineered interdomain disulfide bond stabilizes human blood coagulation factor VIIIa.

Authors:  A J Gale; J-L Pellequer
Journal:  J Thromb Haemost       Date:  2003-09       Impact factor: 5.824

10.  Expression and characterization of recombinant murine factor VIII.

Authors:  Christopher Doering; Ernest T Parker; John F Healey; Heather N Craddock; Rachel T Barrow; Pete Lollar
Journal:  Thromb Haemost       Date:  2002-09       Impact factor: 5.249

View more
  27 in total

1.  Role of hydrophobic mutations on the binding affinity and stability of blood coagulation factor VIIIa: a computational molecular dynamics and free-energy analysis.

Authors:  Divi Venkateswarlu
Journal:  Biochem Biophys Res Commun       Date:  2014-06-18       Impact factor: 3.575

2.  Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.

Authors:  Hironao Wakabayashi; Philip J Fay
Journal:  Biochemistry       Date:  2013-05-21       Impact factor: 3.162

3.  Factor VIII lacking the C2 domain retains cofactor activity in vitro.

Authors:  Hironao Wakabayashi; Amy E Griffiths; Philip J Fay
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

4.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

5.  Mass spectrometry-assisted study reveals that lysine residues 1967 and 1968 have opposite contribution to stability of activated factor VIII.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Carmen van der Zwaan; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

6.  Enhancing factor VIII and VIIIa stability by combining mutations at the A2 domain interface and A1-C2 domain interface.

Authors:  H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

7.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

8.  Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.

Authors:  Lilley Leong; Derek Sim; Chandra Patel; Katherine Tran; Perry Liu; Elena Ho; Thomas Thompson; Peter J Kretschmer; Hironao Wakabayashi; Philip J Fay; John E Murphy
Journal:  Blood       Date:  2014-10-20       Impact factor: 22.113

9.  Effects of replacement of factor VIII amino acids Asp519 and Glu665 with Val on plasma survival and efficacy in vivo.

Authors:  Matthew P Kosloski; Krithika A Shetty; Hironao Wakabayashi; Philip J Fay; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2014-06-17       Impact factor: 4.009

10.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.